Navigation Links
Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)

CAMBRIDGE, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, announced today that three abstracts have been accepted for presentation at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, April 23 - 27, 2008. Full abstracts can now be viewed at the EASL website at

David Standring, Ph.D., Executive Vice President, Biology at Idenix Pharmaceuticals, will present "In Vitro Activity and Pharmacologic Properties of Two Novel Series of HCV Protease Inhibitors" in an oral presentation session at 6:15 p.m. CET on Thursday, April 24, 2008.

Dr. Standring will also present, "Potent Antiviral Activity of Second Generation Nucleoside Inhibitors, IDX102 and IDX184, in HCV-Infected Chimpanzees" in an oral presentation session at 5:30 p.m. CET on Friday, April 25, 2008.

Erika Cretton-Scott, Ph.D., Director, Preclinical Pharmacology at Idenix Pharmaceuticals, will present "In Vitro Antiviral Activity and Pharmacology of IDX184, a Novel and Potent Inhibitor of HCV Replication" in a poster session beginning on Thursday, April 24, 2008.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus and human immunodeficiency virus (HIV). For further information about Idenix, please refer to

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward- looking statements can be identified by implied discussions with respect to the company's clinical development programs in hepatitis C, or any potential pipeline candidates for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, pre-clinical studies and/or clinical trials, including additional data relating to the ongoing pre- clinical studies and/or clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's annual report on Form 10-K for the year ended December 31, 2006 and the Quarterly Report on Form 10- Q for the quarter ended September 30, 2007, each as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Idenix Pharmaceuticals' Contacts:

Media: Teri Dahlman (617) 995-9905

Investors: Amy Sullivan (617) 995-9838

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
(Date:10/8/2015)... Celemics, a global pioneer of personalized medicine ... market with the establishment of Celemics America, Inc. ... Europe , has secured itself in the global ... sample preparation for DNA sequencing and genetic testing.  Next ... genetic testing more accurately, quickly, and cost effectively than ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)... ... October 08, 2015 , ... ProMIS ... license agreement to develop and commercialize intellectual property rights belonging to The University ... February 2009, and affords exclusive worldwide rights to intellectual property based on use ...
(Date:10/7/2015)... Dallas-Fort Worth, Texas (PRWEB) , ... October 07, ... ... Stem Cell Institute ( ) will present a public educational seminar on ... diseases on Saturday, October 10th from 1:00 pm – 3:00 pm at the ...
Breaking Biology Technology:
... Nov. 28 On Monday, December 1, 2008, at,8:30 ... Therapeutics, Inc.,s (CTI) (Nasdaq and MTA: CTIC) management team ... Spectrum Pharmaceuticals,of Irvine, California to jointly market and develop ... Call Numbers, Monday, December 1, ...
... today that it is refocusing all projects and priorities around ... be seen as a,consequence of the negative recommendation of the ... 2008 regarding the,approval of Iclaprim in the U.S. , ... FDA advisory board,s recommendation the Arpida,board intends to put the ...
... house always looking good, without cleaning or giving it ... with paint that can maintain itself and get rid ... process for producing photo-catalytic, self-cleaning coatings has been developed ... and Research), and licensed to Haruna (S) Pte Ltd. ...
Cached Biology Technology:
(Date:9/24/2015)... YORK , Sept. 24, 2015  EyeLock LLC, ... be showcasing its award winning and latest technology in ... Anaheim, California . EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
(Date:9/10/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market, announces that the San ... will feature the Wocket® smart wallet for the first ... Touch Of Modern is an online retailer ... its 7.2 million members. Customers are affluent, urban influencers ...
Breaking Biology News(10 mins):
... and their colleagues in Japan are conducting research that may ... necessary step if man someday hopes to build molecular machines ... Dr. Eric Blough, a member of the research ... Biological Sciences, said his group has shown how bionanomotors can ...
... Biologists have known for long that ecology, the interaction ... in forming new species and in modifying living ones. ... The environment defines a template and the process of ... template. Some specialized theory, a few ...
... plant virus lures aphids to infected plants by making the ... they quickly leave for tastier, healthier ones. In the process, ... entomologists. "The virus improves the cues that insects use to ... is already in the plant," said Mark C. Mescher, assistant ...
Cached Biology News: